Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Non-small Cell Lung Carcinoma

NCT02448303 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02448303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02448303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Non-small Cell Lung Carcinoma
Lead sponsor
Acerta Pharma BV
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
June 30, 2018
Enrollment
74 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung